|
Partheneon Bioregents manufacturers and sells degradation resistant proteins in the Homeobox (Hox) family. Hox proteins contain a conserved homeodomain. Parthenon Bioreagents has discovered a patented set of point mutations (Hox+) that prevent ubiquination of the protein, thereby increasing the effective intracellular dose and duration of the protein without compromising bioactivity. Parthenon proteins also possess a cell penetrating peptide motif based on HIV-TAT for generalized uptake.
|
|
|
|
Cost savings. |
Convenience. |
New studies. |
|
Depending on cell type, Hox+ protein intracellular halflife is ~5X greater than wildtype proteins. This higher effective dose drastically reduces the amount of protein required to achieve bioactivity.
|
The short natural half-life of wildtype Hox proteins often requires frequent dosing, potentially every few hours. Hox+ proteins can simplify experimental protocols to avoid the need for 24/7 staff availability and to decongest lab logistics.
|
Laboratories studying Hox genes often work with knock outs (KOs) or enforced overexpression. Proteins can enable controlled gain-of-function experiments.
|